The FDA's latest push to boost women and minorities' representation in clinical studies is not enough, critics said. The agency should require drugmakers to conduct more inclusive trials to guarantee that drugs are effective and safe for women, said Cynthia Pearson of the National Women's Health Network. Drugmakers have no incentive to improve as long as drugs are being approved, the National Center for Health Research's Diana Zuckerman said.

Related Summaries